Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.
Clear decision-making data for your project team is vital to ensure you avoid costly issues related to QTc and QRS cardiac liabilities in the clinic.
Hear from industry experts, Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company) and Steve Jenkinson (Metrion).
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.
Alex Haworth, Senior Scientist at Metrion, introduces a poster demonstrating Metrion's development of a monoclonal CHO cell line expressing hNav1.9, validated via manual and automated patch clamp techniques.